Key Takeaways
- Kremlin envoy Kirill Dmitriev met with US officials in New York to discuss a peaceful resolution to the war in Ukraine and post-war energy initiatives.
- Eli Lilly (LLY) announced that Zepbound achieved a 20.2% weight reduction at 72 weeks, significantly outperforming Novo Nordisk’s Wegovy (13.7%).
- Deutsche Bank upgraded Netflix (NFLX) to Buy from Hold, citing an undervalued growth outlook despite cutting the price target to $95.
- Brazil’s FGV Inflation (IGP-M) for September rose 1.57%, exceeding market estimates of 1.55% and marking a sharp reversal from August's deflation.
- Rosatom and Iran are in active discussions to build new nuclear power plants as Russian specialists return to the Bushehr facility.
Diplomatic Breakthroughs: US-Russia and US-Iran Talks
A senior US official confirmed that Putin’s envoy, Kirill Dmitriev, held "constructive" meetings on Monday with US representatives. The discussions focused on a peaceful resolution to the conflict in Ukraine and explored possible US-Russia energy initiatives once the war concludes. These talks follow a series of high-level meetings in New York aimed at establishing a dialogue for long-term regional stability.
Simultaneously, mediators are working toward a US-Iranian understanding to revive the "Islamabad Understanding." While both Washington and Tehran have expressed frustration over current negotiation results, Qatar continues to facilitate the transfer of messages. These efforts come as Rosatom specialists return to Iran’s Bushehr nuclear plant to resume construction on units 2 and 3, following previous evacuations.
Healthcare: Eli Lilly’s Zepbound Dominates Clinical Trials
Eli Lilly (LLY) released updated clinical data showing its obesity drug Zepbound delivered a 20.2% mean weight reduction over 72 weeks. This result places the drug firmly ahead of its primary competitor, Novo Nordisk’s Wegovy, which saw a 13.7% reduction in the same timeframe. The data, presented at the European Association for the Study of Diabetes, also highlighted that Zepbound users were significantly more likely to achieve a 20% or greater reduction in body weight.
Tech and Media: Deutsche Bank Upgrades Netflix
Deutsche Bank analysts upgraded Netflix (NFLX) to Buy, arguing that the streaming giant’s current valuation—trading at roughly 18 times 2027 earnings estimates—undervalues its healthy growth trajectory. Although the bank lowered its price target to $95 from $100 due to revised free cash flow estimates, the new target still implies a 37% upside from recent lows. Analysts noted that while subscriber engagement remains a focus, the stock's year-to-date decline has created a compelling entry point for investors.
Industrial and Macro Trends: BYD Leadership and Brazil Inflation
In the automotive sector, BYD (BYDDF) confirmed the appointment of founder Wang Chuanfu as Company President. The move comes as BYD continues its aggressive global expansion, with Wang recently stating the company aims to become the world’s largest automaker within five years. This leadership consolidation occurs as German industry shifts its stance on China, with the BDI warning that "passivity" in de-risking would be more economically costly than active strategic adjustments.
On the macroeconomic front, Brazil's IGP-M inflation index surged 1.57% in September, a significant jump from the -0.22% recorded in August. The figure was slightly higher than the 1.55% expected by analysts, bringing the year-over-year inflation rate to 3.34%. The rise is largely attributed to wholesale price volatility and serves as a key indicator for upcoming rental and utility contract adjustments in the region.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.